SG Americas Securities’s CureVac CVAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-17,574
| Closed | -$79K | – | 3338 |
|
|
2025
Q4 | $79K | Buy |
+17,574
| New | +$90K | ﹤0.01% | 3282 |
|
|
2024
Q1 | – | Sell |
-25,474
| Closed | -$107K | – | 3055 |
|
|
2023
Q4 | $107K | Sell |
25,474
-6,023
| -19% | -$32.7K | ﹤0.01% | 2717 |
|
|
2023
Q3 | $215K | Buy |
31,497
+19,259
| +157% | +$170K | ﹤0.01% | 2278 |
|
|
2023
Q2 | $128K | Sell |
12,238
-2,674
| -18% | -$23.9K | ﹤0.01% | 1987 |
|
|
2023
Q1 | $104K | Sell |
14,912
-495
| -3% | -$4.32K | ﹤0.01% | 2883 |
|
|
2022
Q4 | $93K | Buy |
15,407
+1,526
| +11% | +$11.3K | ﹤0.01% | 2743 |
|
|
2022
Q3 | $109K | Buy |
13,881
+2,256
| +19% | +$26.3K | ﹤0.01% | 2799 |
|
|
2022
Q2 | $158K | Buy |
11,625
+624
| +6% | +$10.3K | ﹤0.01% | 2836 |
|
|
2022
Q1 | $216K | Sell |
11,001
-216,619
| -95% | -$4.33M | ﹤0.01% | 2385 |
|
|
2021
Q4 | $7.81M | Buy |
227,620
+220,107
| +2,930% | +$8.86M | 0.04% | 338 |
|
|
2021
Q3 | $410K | Sell |
7,513
-135
| -2% | -$8.13K | ﹤0.01% | 2683 |
|
|
2021
Q2 | $562K | Sell |
7,648
-24,238
| -76% | -$2.42M | ﹤0.01% | 1886 |
|
|
2021
Q1 | $2.92M | Buy |
31,886
+20,964
| +192% | +$2.03M | 0.02% | 797 |
|
|
2020
Q4 | $885K | Buy |
+10,922
| New | +$836K | ﹤0.01% | 1604 |
|
SG Americas Securities's CVAC Position: Q1 2026 in Review
SG Americas Securities sold out of CureVac (CVAC) in Q1 2026, closing a stake of 17,574 shares — an estimated $79K sold.
SG Americas Securities first reported a position in CVAC in Q4 2020 and held it in 14 quarters. The position peaked at $7.81M in Q4 2021. 0 funds tracked by Wall St. Rank hold CVAC as of Q1 2026.
- SG Americas Securities reported no remaining CureVac position as of Q1 2026 after selling out during the quarter.
- SG Americas Securities sold 17,574 CureVac shares in Q1 2026, an estimated $79K.
- SG Americas Securities first reported a position in CureVac in Q4 2020 and held it in 14 quarters.
- SG Americas Securities's CureVac position peaked at $7.81M in Q4 2021.
- 0 funds tracked by Wall St. Rank held CureVac as of Q1 2026.
Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.